trend toward significancep = 0.056
However a benefit of aRT over esRT on these long-term outcomes might exist, especially given the statistical benefit of aRT on 15-year metastasis-free survival ( p = 0.036) and the trend toward significance regarding overall survival ( p = 0.056) [ 6 ]. aRT also significantly reduces the need for subsequent androgen deprivation therapy, which is known for its inherent toxicity [ 36 ].